HOOKIPA Biotech GmbH
Hookipa Biotech GmbH
Helmut-Qualtinger-Gasse 2
Vienna
1030
Austria
Website: http://www.hookipapharma.com/
About HOOKIPA Biotech GmbH
55 articles with HOOKIPA Biotech GmbH
-
HOOKIPA to Participate in the Sidoti Micro-Cap Virtual Conference
11/2/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that the company will participate in the Sidoti Micro-Cap Virtual Conference, November 9 - 10, 2022.
-
Roche and Austria-based Hookipa Pharma tied up a licensing and research and development collaboration valued at more than $950 million focused on KRAS-mutated cancers.
-
HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates
8/11/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapies based on its proprietary arenavirus platform, reported financial results for the second quarter of 2022 and Company updates.
-
FDA accepts HOOKIPA’s Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer
7/25/2022
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, has received U.S. Food and Drug Administration (FDA) acceptance of its Investigational New Drug (IND) application for HB-300, a novel arenaviral immunotherapy for the treatment of metastatic castration-resistant prostate cancer.
-
There were multiple leadership changes in the biopharma industry, with several new chief executive officers tapped to guide companies through their next growth phases.
-
HOOKIPA Announces Executive Leadership Changes
6/21/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced several leadership changes as the company expands its clinical development and pipeline programs.
-
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
6/5/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced positive Phase 1 results from its HB-200 program evaluating single-vector HB-201 and alternating 2-vector HB-202/HB-201 in advanced Human Papillomavirus 16-positive head and neck cancer patients.
-
Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium
6/3/2022
Oral and poster presentations highlight robust and high-quality immune responses following administration of novel arenaviral therapeutic vaccines in preclinical setting.
-
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO
5/26/2022
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), today announced that complete HB-200 Phase 1 results (NCT04180215) for single-vector HB-201 and alternating 2-vector HB-202/HB-201 in patients with advanced Human Papillomavirus 16-positive (HPV16+) cancers, including the recommended Phase 2 dose for HB-202/HB-201, will be shared in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
HOOKIPA Pharma Reports First Quarter 2022 Financial Results and Recent Highlights
5/16/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported financial results and business highlights for the first quarter of 2022.
-
HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022
5/9/2022
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2022 financial results before the market open on Monday, May 16, 2022.
-
BioSpace Movers & Shakers, May 6
5/6/2022
Biopharma and life sciences companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers. -
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May 2022
5/3/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that HOOKIPA’s management team will participate in and present at the following upcoming investor conferences:
-
HOOKIPA announces promotion of Christine D. Baker to Chief Operating Officer
5/2/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced the promotion of Christine D. Baker to Chief Operating Officer effective immediately.
-
HOOKIPA Pharma Appoints Tim Reilly, Ph.D. to its Board of Directors
4/20/2022
HOOKIPA Pharma Inc. today announced the appointment of Tim Reilly, Ph.D. to its Board of Directors, effective immediately.
-
The AACR annual meeting concluded on April 13, showcasing hundreds of preclinical to late-stage information from ongoing studies on treatment candidates.
-
New data show HOOKIPA’s arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens
4/13/2022
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), today announced positive preclinical data demonstrating potent T cell responses, potential novel combination use beyond PD-1 inhibitors, and the ability to break immune tolerance to various self-antigens for targeting cancers.
-
HOOKIPA to Participate in the Kempen Life Sciences Conference - Apr 13, 2022
4/13/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that the company will participate in investor meetings at the Kempen Life Sciences Conference being held in Amsterdam, April 20 - 21, 2022.
-
HOOKIPA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Outlook
3/24/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported financial results and provided a corporate update for the fourth quarter and full year 2021, as well as outlook for 2022.
-
HOOKIPA Announces Promotion of Klaus Orlinger, Ph.D. to Chief Scientific Officer
3/22/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that Klaus Orlinger, Ph.D. has been promoted to Chief Scientific Officer.